Zensun Sci & Tech

Zensun Sci & Tech is a pioneering Chinese biotech with a 20+ year history, dedicated to discovering and developing original, first-in-class medicines. Its lead asset, Neucardin® (recombinant human neuregulin-1), is a novel biologic for heart failure that has received FDA Fast Track designation and is the centerpiece of a pipeline targeting cardiology and oncology. The company successfully raised approximately $76 million in funding, positioning it to advance its clinical programs and expand its global footprint through strategic research collaborations.

Platform focused on cardiomyocyte therapy and energy metabolism, leveraging deep research into cell signaling (e.g., neuregulin-1/ErbB pathway) to develop disease-modifying biologics and gene therapies that repair and regenerate heart muscle.

Zensun competes in the crowded heart failure market against large pharma and established drug classes (SGLT2 inhibitors, ARNIs). Its key differentiator is a first-in-class, disease-modifying approach targeting myocardial repair, a mechanism not directly addressed by current therapies, which primarily manage hemodynamics and neurohormonal activation.